The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Sanofi Invests $27 Million in Ventyx Biosciences for VTX3232 Program
Sep 23, 2024•over 1 year ago
Contract Type
partnership
San DiegoOtherBiotechnology
Description
Ventyx Biosciences, Inc. has announced a strategic investment of $27 million from Sanofi, a global leader in immunological and inflammatory diseases. The investment is for the VTX3232 program, which offers a disease-modifying approach for the treatment of neuroinflammatory conditions with high unmet medical need.
Company Information
Company
Ventyx Biosciences
Location
12790 EL CAMINO REAL, SUITE 200
San Diego, California, United States
About
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need.
San DiegoOtherBiotechnology